Agios Pharmaceuticals (AGIO) Projected to Release Earnings on Thursday

Key Points

• Agios Pharmaceuticals is expected to report Q3 2026 results before market open on November 5. Analysts project a loss of $1.25 per share and revenue of $51.55 million.
• The company reported a wider-than-expected Q2 loss of $1.69 per share, although revenue of $44.75 million exceeded estimates. Analysts expect full-year and next-year losses of $5.83 and $4.18 per share, respectively.
• AGIO has a Moderate Buy consensus rating and an average price target of $41.50, compared with a recent price of $38.12; however, insiders sold approximately $1.29 million of shares during the last quarter.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) is expected to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Agios Pharmaceuticals to post earnings of ($1.25) per share and revenue of $51.55 million for the quarter. Investors are encouraged to explore the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.65) by ($0.04). Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. The firm had revenue of $44.75 million during the quarter, compared to analyst estimates of $26.39 million. On average, analysts expect Agios Pharmaceuticals to post ($5.83) EPS for the current fiscal year and ($4.18) EPS for the next fiscal year.

Agios Pharmaceuticals Stock Performance

AGIO stock opened at $38.12 on Thursday. Agios Pharmaceuticals has a one year low of $22.24 and a one year high of $46.00. The stock has a market capitalization of $2.28 billion, a PE ratio of -5.44 and a beta of 0.63. The company has a fifty day moving average of $33.64 and a 200-day moving average of $31.65.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 30,000 shares of the stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $30.48, for a total value of $914,400.00. Following the completion of the transaction, the insider owned 54,645 shares in the company, valued at approximately $1,665,579.60. This represents a 35.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 39,855 shares of company stock worth $1,285,512 over the last quarter. Corporate insiders own 5.40% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. TD Cowen raised shares of Agios Pharmaceuticals to a "strong-buy" rating in a report on Monday, August 24th. Citigroup increased their price target on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a "buy" rating in a report on Friday, July 31st. Bank of America raised their price objective on shares of Agios Pharmaceuticals from $46.00 to $50.00 and gave the company a "buy" rating in a research report on Monday, September 21st. HC Wainwright raised their price objective on shares of Agios Pharmaceuticals from $52.00 to $55.00 and gave the company a "buy" rating in a research report on Thursday, July 30th. Finally, JPMorgan Chase & Co. lifted their price objective on Agios Pharmaceuticals from $31.00 to $34.00 and gave the company a "neutral" rating in a report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $41.50.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company's research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios' principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.